$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
卡博替尼在肝细胞癌中的应用:2期安慰剂对照研究结果
2025-10-19 11:44:20
Check Details
仑伐替尼治疗甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌有效率
2025-10-19 11:44:20
Check Details
乐伐替尼治疗放射性碘治疗失败分化型甲状腺癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗甲状腺髓样癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗甲状腺髓样癌的效果
2025-10-19 11:44:20
Check Details
卡博替尼治疗甲状腺髓样癌的推荐剂量
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌无进展生存期显著延长
2025-10-19 11:44:20
Check Details
卡博替尼延长甲状腺随样癌无进展生存期
2025-10-19 11:44:20
Check Details
甲状腺癌患者服用索拉非尼的治疗效果怎么样?
2025-10-19 11:44:20
Check Details
不止肝癌肾癌,索拉菲尼也可用于治疗甲状腺癌!
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌延长无进展生存期
2025-10-19 11:44:20
Check Details
1
2
...
8517
8518
8519
8520
8521
8522
8523
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
2
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
3
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
4
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
5
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
6
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
7
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
8
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
9
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
10
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
11
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
12
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend